A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer.

@article{Manegold2012API,
  title={A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer.},
  author={Christian Manegold and Nico van Zandwijk and Alexandra Szczesna and Peter Zatloukal and Joseph Siu Kai Au and Maria Blasinska-Morawiec and Piotr Serwatowski and Maciej Jerzy Krzakowski and Jacek Jassem and E. H. Tan and Rebecca J. Benner and Annapaola Ingrosso and Sandra J Meech and David Readett and Nicholas Thatcher},
  journal={Annals of oncology : official journal of the European Society for Medical Oncology},
  year={2012},
  volume={23 1},
  pages={72-7}
}
BACKGROUND This open-label phase III study assessed the addition of Toll-like receptor 9-activating oligodeoxynucleotide PF-3512676 to gemcitabine/cisplatin chemotherapy in patients with non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS Chemotherapy-naive patients with stage IIIB or IV NSCLC were randomized (1:1) to receive six or fewer 3-week cycles of i.v. gemcitabine (1250 mg/m2 on days 1 and 8) and cisplatin alone (75 mg/m2 on day 1, control arm) or combined with s.c. PF-3512676 0… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 39 extracted citations

Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?

Expert review of anticancer therapy • 2014
View 6 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…